IPM Take
Migraine patients have waited too long to be believed. That does not mean every biomarker should be believed before it earns the role.
CGRP has changed migraine treatment. That is clear. But a treatment target is not automatically a diagnostic blood test. The new Danish registry data are useful precisely because they push back against an attractive shortcut.
Migraine needs better tools. It also needs the humility to admit when biology is more complicated than the test we wanted.
Executive Summary
A study published in Neurology examined whether plasma calcitonin gene-related peptide, or CGRP, can serve as a diagnostic biomarker for migraine.
Using data from the Danish REFORM registry, investigators compared people with migraine and healthy controls and assessed whether plasma CGRP levels varied by migraine subtype, disease state and clinical characteristics.
The study reported that plasma CGRP concentrations were not higher in migraine and were not useful as a diagnostic discriminator. Public reporting of the study noted that the analysis included more than 1,700 participants, including people with episodic and chronic migraine.
The findings do not undermine CGRP as a therapeutic pathway. Anti-CGRP and CGRP-receptor therapies remain central to migraine prevention and treatment. The point is narrower and important: circulating CGRP levels in plasma do not appear ready to function as a simple diagnostic biomarker for migraine.
Why it matters
- Patients / advocates: Migraine patients need validation and better diagnosis, but a weak biomarker risks replacing one form of dismissal with another.
- Clinicians: Clinical diagnosis remains central. Plasma CGRP should not be used as a shortcut to confirm or exclude migraine.
- Diagnostics / pathology: A biologically relevant pathway does not automatically produce a clinically useful blood test.
- Researchers / academia: The findings sharpen the question of which biomarkers, sample types and timing could better capture migraine biology.
Migraine has always suffered from an evidence paradox.
The disease is disabling, common and biologically real. Yet because it often leaves no visible injury on a scan and no simple abnormality on a routine test, patients are repeatedly forced to translate pain into credibility.
That is why the idea of a blood biomarker is so tempting.
A test could make migraine visible. It could support diagnosis, reduce doubt and help stratify patients. CGRP seemed an obvious candidate because therapies targeting CGRP biology have transformed parts of migraine care.
The Danish data complicate that story.
The study suggests that plasma CGRP does not reliably separate people with migraine from healthy controls. It also challenges the assumption that a pathway validated by treatment response must show up cleanly in peripheral blood. Migraine biology is dynamic, tissue-specific and influenced by timing, disease state and individual variation. A single plasma measurement may simply be too blunt.
That is not a defeat for precision neurology. It is precision neurology doing its job.
The field should want biomarkers that fail when they are not good enough. Otherwise, diagnostics become decorative: attractive, publishable and clinically weak.
Patients do not need a blood test that sounds scientific but cannot guide care. They need faster recognition, better access to evidence-based prevention, fewer dismissive encounters and tools that improve decisions rather than create false confidence.
Migraine still needs better biomarkers. Plasma CGRP may not be the one.
